Erste Asset Management - Blog

Artikel zu Schlagwort: Astrazeneca
http://blog.en.erste-am.com/wp-content/uploads/sites/13/2017/08/Fotolia_126038046_L-890x390.jpg
Gast-AutorIn / Guest Author am 04th September 2017

Tailwind for biotechnology companies

(c) Fotolia

Author: Harald Kober, Senior Fundmanager

“Breather” coming to an end

Biotechnology shares have been among the top performers in the past ten years. After the above-average performance from 2010 to the beginning of 2015, hedge funds set off a consolidation that is now coming to an end. The NASDAQ biotechnology index, the most important barometer for biotech shares, has gained 25% in the year to date (source: Reuters Datastream, as of 31 August 2017). Read more

Subscribe to Blog by E-Mail